-
Mashup Score: 19
Diagnosing genetic disorders requires extensive manual curation and interpretation of candidate variants, a labor-intensive task even for trained geneticists. Although artificial intelligence (AI) …
Source: ai.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma - 1 month(s) ago
Nature Communications – The downstream molecular mechanisms following the activation of the NF-κB pathway in multiple myeloma (MM) remain to be characterised. Here, it is shown that aberrant…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58
Nature – Antibody-mediated depletion of myeloid-biased haematopoietic stem cells in aged mice restores characteristic features of a more youthful immune system.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma - 2 month(s) ago
Summary:. While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 31Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma - 2 month(s) ago
Summary:. While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 26Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma - 2 month(s) ago
Summary:. While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0U.S. Senate confirms Monica Bertagnolli as NIH director - 6 month(s) ago
After 2-year gap, biomedical research agency has a permanent chief, but she faces many challenges
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Walter Michael Kuehl, MD - October 25, 1939 - April 30, 2023 | Published in Clinical Hematology International - 7 month(s) ago
By Leif Bergsagel. Mike left an indelible mark on the people fortunate enough to train in his laboratory.
Source: chi.scholasticahq.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Nature – Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Scientists have fully sequenced the Y chromosome for the first time, uncovering information that could have implications for the study of male infertility and other health problems.
Source: www.cnn.comCategories: Hem/Oncs, Latest HeadlinesTweet
RT @zakkohane: Improving the genetic diagnosis of the undiagnosed with AI @NEJM_AI https://t.co/DXrLOPMcyT Random-forest modules trained on…